{
  "abstract": "Background and Importance The use of pro-protein convertase subtilisine/kexin 9 inhibitors (PCSK9i) for the treatment of hypercholesterolaemia require long-term monitoring. Close follow-up of these treatments is necessary to assess potential treatment intensifications based on levels, risks, and therapeutic ceilings, individualising each case.Aim and Objectives To evaluate pharmaceutical interventions in patients with hypercholesterolaemia treated with PCSK9i (alirocumab or evolocumab).To assess the acceptance rate of the interventions.Material and Methods Retrospective observational study of pharmaceutical interventions performed in patients with hypercholesterolaemia treated with PCSK9i since the inclusion of these drugs in the hospital guidelines (August 2016–February 2025) at a tertiary care hospital. Data collected: age, sex, lipid-lowering treatment, adherence, pharmaceutical interventions, treatment changes.Results During the study period, 52 patients receiving PCSK9i treatment were included (28 men) with a median age of 64 years (IQR: 16–84). The median duration of treatment was 39 months (IQR: 4–100). In addition to monoclonal antibodies, 62% of patients were on concomitant treatment (statins, ezetimibe, and/or bempedoic acid). Sixty-five percent were statin-intolerant. Adherence to hospital medication collection was 95.4% compared to 78.9% in primary care. Nineteen interventions were carried out in 17 different patients, with an acceptance rate of 89.5%. The most common intervention was an increase in alirocumab dose (68.4%). Other interventions included switching and addition of oral treatments.Conclusion and Relevance Close monitoring by the pharmacy department benefits: Early detection of analytical worsening, therapeutic failures, and patient transgressions. Higher adherence in hospital settings compared to community care. The high acceptance rate of interventions confirms the need for a multidisciplinary approach for better management of these patients.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Santos Reyes, Hospital Pharmacy, Aranda De Duero, Spain"
      ],
      "name": "V Benito Ibáñez"
    },
    {
      "affiliations": [
        "Hospital Santos Reyes, Hospital Pharmacy, Aranda De Duero, Spain"
      ],
      "name": "A Codonal Demetrio"
    },
    {
      "affiliations": [
        "Hospital Santos Reyes, Hospital Pharmacy, Aranda De Duero, Spain"
      ],
      "name": "B Oca Luis"
    },
    {
      "affiliations": [
        "Hospital Santos Reyes, Internal Medicine, Aranda De Duero, Spain"
      ],
      "name": "C Hernando Martín"
    },
    {
      "affiliations": [
        "Hospital Santos Reyes, Internal Medicine, Aranda De Duero, Spain"
      ],
      "name": "MV Pardo Gutierrez"
    }
  ],
  "title": "4CPS-015 Pharmacist’s role in the follow-up of patients treated with PCSK9i inhibitors",
  "uid": "5c0ae7b1-4fc7-5c36-8e1d-db000903d29c"
}